CJClare Therese Johnson

Clare Therese Johnson

*This is an algorithmically generated author record based on publicly available information.

Clare Therese Johnson has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perinatal cannabidiol exposure reshapes astrocyte morphology and tripartite synapse organization in a sex-dependent manner

    by Gabriel Henrique Dias de Abreu, Jeremy Wilson, Vitor Ritzmann, Oscar John Moosbrugger, Clare Therese Johnson, Ken Mackie, Heather Bradshaw, Jui-Yen Huang, Hui-Chen Lu

    Cannabidiol (CBD) has recently gained significant public acceptance as a safe therapeutic, contributing to increased use during pregnancy. However, little is known about how maternal CBD exposure impacts fetal brain development. Here, we established a preclinical CBD perinatal exposure (CBD-PCE) model to examine the impacts of CBD on astrocyte morphology in the medial prefrontal cortex (mPFC), a brain region critical for working memory and affective behaviors. Astrocytes play critical roles in maintaining ionic/metabolic homeostasis, neurotransmission, and neurovascular coupling in the CNS. They exhibit highly ramified processes with endfeet surrounding synapses, forming tripartite synapses. We quantitatively assessed the impact of CBD-PCE on astrocyte morphology and the composition of tripartite synapses in mPFC using high-resolution three-dimensional (3D) imaging. Our morphometric analyses revealed that CBD-PCE reduced astrocyte density and increased the number of major branches and whole-cell volume in the mPFC of male, but not female, progenies. Using high-magnification 3D analysis, we found that mPFC astrocytes after CBD-PCE exhibited increased neuropil infiltration volume and reduced surface-to-volume ratios in males but not in females. Moreover, the levels of aquaporin-4 (AQP4) and Kir4.1 inwardly rectifying potassium channel, two key components in regulating ionic homeostasis, are elevated on the membranes of male CBD-PCE astrocytes. We also analyzed mPFC tripartite synapses and observed significant increases in thalamocortical tripartite synapse density in both sexes, whereas intracortical excitatory synapses were reduced only in females. Collectively, these findings demonstrate that CBD-PCE induces sex-specific changes in astrocyte morphology and in the composition of tripartite synapses in the mPFC of the progeny's brains.


  • Cannabidiol abrogates cue-induced anxiety associated with normalization of mitochondria-specific transcripts and linoleic acid in the nucleus accumbens shell

    by Jacqueline-Marie N. Ferland, Alexandra Chisholm, Jasmina Abdalla, Resat Cinar, Clare Johnson, Heather B. Bradshaw, Yasmin L. Hurd

    Anxiety disorders are one of the top contributors to psychiatric burden worldwide. Recent years have seen a dramatic rise in the potential anxiolytic properties ascribed to cannabidiol (CBD), a non-intoxicating constituent of the Cannabis Sativa plant. This has led to several clinical trials underway to examine the therapeutic potential of CBD for anxiety disorders. Yet, CBD’s anxiolytic effects are mixed with some studies reporting little to no impact on trait anxiety but significant reductions in pathological anxiety with suggestions that CBD’s effect may relate to triggered or cue-induced behavior. Here, we studied the effects of CBD on cued and non-cued behaviors and related neurobiological underpinnings. To investigate the effect of CBD on cue-induced anxiety, male rats underwent a fear conditioning protocol (odor associated with shock) followed by assessments of avoidance behavior. CBD (10 mg/kg) was administered 1 h prior to anxiety assessments. To understand molecular mechanisms associated with behavior, we investigated the transcriptome and lipid profile of the nucleus accumbens shell (NAcSh), a structure implicated in cue-mediated behaviors and aversion. Administration of CBD significantly reduced avoidance behavior, but only in animals repeatedly exposed to a shock-paired cue. CBD did not affect behavior in animals exposed to neutral cue or encoding of the cue behavioral response. RNA sequencing revealed substantial impact of the shock-paired cue in control animals, recruiting mechanisms ranging from cytoskeletal dynamics to mitochondria dysfunction. The shock-paired cue also resulted in elevated linoleic acid in vehicle animals which correlated with anxiety-like behavior. CBD either reversed or normalized these cue-induced molecular phenotypes. CBD also recruited lipid networks which correlated with transcripts involved in synaptic plasticity, signaling, and epigenetic mechanisms. These results suggest that CBD may specifically alleviate salient, conditioned anxiety and normalize related biological mechanisms in the NAcSh which may guide therapeutic interventions for anxiety disorders.


  • Open Access

    Cannabinoids accumulate in mouse breast milk and differentially regulate lipid composition and lipid signaling molecules involved in infant development

    by Clare Therese Johnson, Gabriel H Dias de Abreu, Ken Mackie, Hui-Chen Lu, Heather B Bradshaw

    Maternal cannabis use during lactation may expose developing infants to cannabinoids (CBs) such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBs modulate lipid signaling molecules in the central nervous system in age- and cell-dependent ways, but their influence on the lipid composition of breastmilk has yet to be established. This study investigates the effects of THC, CBD, or their combination on milk lipids by analyzing the stomach contents of CD1 mouse pups that have been nursed by dams injected with CBs on postnatal days (PND) 1-10 collected 2 hours after the last injection on PND10. HPLC/MS/MS was used to identify and quantify over 80 endogenous lipid species and cannabinoids in pup stomach contents. We show that CBs differentially accumulate in milk, lead to widespread decreases in free fatty acids, decreases in N -acyl methionine species, increases N -linoleoyl species, as well as modulate levels of endogenous CBs (eCBs) AEA, 2-AG, and their structural congeners. Our data indicate the passage of CBs to pups through breast milk and that maternal CB exposure alters breast milk lipid compositions.

  • Open Access

    Monoacylglycerol Lipase Inhibitor MJN110 Reduces Neuronal Hyperexcitability, Restores Dendritic Arborization Complexity, and Regulates Reward-Related Behavior in Presence of HIV-1 Tat

    by Alexis F. League, Benjamin L. Gorman, Douglas J. Hermes, Clare T. Johnson, Ian R. Jacobs, Barkha J. Yadav-Samudrala, Justin L. Poklis, Micah J. Niphakis, Benjamin F. Cravatt, Aron H. Lichtman, et al.

    While current therapeutic strategies for people living with human immunodeficiency virus type 1 (HIV-1) suppress virus replication peripherally, viral proteins such as transactivator of transcription (Tat) enter the central nervous system early upon infection and contribute to chronic inflammatory conditions even alongside antiretroviral treatment. As demand grows for supplemental strategies to combat virus-associated pathology presenting frequently as HIV-associated neurocognitive disorders (HAND), the present study aimed to characterize the potential utility of inhibiting monoacylglycerol lipase (MAGL) activity to increase inhibitory activity at cannabinoid receptor-type 1 receptors through upregulation of 2-arachidonoylglycerol (2-AG) and downregulation of its degradation into proinflammatory metabolite arachidonic acid (AA). The MAGL inhibitor MJN110 significantly reduced intracellular calcium and increased dendritic branching complexity in Tat-treated primary frontal cortex neuron cultures. Chronic MJN110 administration in vivo increased 2-AG levels in the prefrontal cortex (PFC) and striatum across Tat(+) and Tat(–) groups and restored PFC N-arachidonoylethanolamine (AEA) levels in Tat(+) subjects. While Tat expression significantly increased rate of reward-related behavioral task acquisition in a novel discriminative stimulus learning and cognitive flexibility assay, MJN110 altered reversal acquisition specifically in Tat(+) mice to rates indistinguishable from Tat(–) controls. Collectively, our results suggest a neuroprotective role of MAGL inhibition in reducing neuronal hyperexcitability, restoring dendritic arborization complexity, and mitigating neurocognitive alterations driven by viral proteins associated with latent HIV-1 infection.


  • Modulatory Potential of Cannabidiol on the Opioid-Induced Inflammatory Response

    by Clare T. Johnson, Heather B. Bradshaw

    Opioids are effective analgesics; however, there are many negative consequences of chronic use. One important side effect of chronic opioid use is the continuous engagement of the immune response that can exacerbate chronic pain. The opioid, morphine, initiates a Toll-like receptor 4 (TLR4) signaling cascade that drives the activation of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome proteins, resulting in cytokine production and effectively creating a positive feedback loop for continuous TLR4 activation. In addition to driving cytokine production, morphine drives changes in proinflammatory lipid signaling. The alteration of both cytokine and lipid signaling systems by morphine suggests that its chronic use leads to a pathological immune response that would benefit from targeted therapy. Engaging the endogenous cannabinoid system has shown therapeutic benefit, particularly regarding its anti-inflammatory and immunosuppressive effects. Promising preclinical and clinical investigations suggest that cannabidiol (CBD) is an effective adjuvant for treatment of symptoms of opioid use disorders; however, the mechanism through which CBD drives this outcome is unclear. One potential source of insight into this mechanism is in how CBD regulates immune regulators such as cytokines and lipid signaling systems, including endocannabinoids and related immune-responsive lipids. In this review, we outline the immune response to chronic opioid use as well as CBD in the context of a lipopolysaccharide-induced immune response and speculate on the mechanism of CBD as a modulator of chronic opioid-induced immune system dysregulation.